Fatty acyl-chain remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport

  1. Tomomi Hashidate-Yoshida
  2. Takeshi Harayama
  3. Daisuke Hishikawa
  4. Ryo Morimoto
  5. Fumie Hamano
  6. Suzumi M Tokuoka
  7. Miki Eto
  8. Miwa Tamura-Nakano
  9. Rieko Yanobu-Takanashi
  10. Yoshiko Mukumoto
  11. Hiroshi Kiyonari
  12. Tadashi Okamura
  13. Yoshihiro Kita
  14. Hideo Shindou
  15. Takao Shimizu  Is a corresponding author
  1. National Center for Global Health and Medicine, Japan
  2. National Center for Global Health and Medicine, Switzerland
  3. The University of Tokyo, Japan
  4. RIKEN Center for Developmental Biology, Japan

Abstract

Polyunsaturated fatty acids (PUFAs) in phospholipids affect the physical properties of membranes, but it is unclear which biological processes are influenced by their regulation. For example, the functions of membrane arachidonate that are independent of a precursor role for eicosanoid synthesis remain largely unknown. Here, we show that the lack of lysophosphatidylcholine acyltransferase 3 (LPCAT3) leads to drastic reductions in membrane arachidonate levels, and that LPCAT3-deficient mice are neonatally lethal due to an extensive triacylglycerol (TG) accumulation and dysfunction in enterocytes. We found that high levels of PUFAs in membranes enable TGs to locally cluster in high density, and that this clustering promotes efficient TG transfer. We propose a model of local arachidonate enrichment by LPCAT3 to generate a distinct pool of TG in membranes, which is required for normal directionality of TG transfer and lipoprotein assembly in the liver and enterocytes.

Article and author information

Author details

  1. Tomomi Hashidate-Yoshida

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  2. Takeshi Harayama

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Switzerland
    Competing interests
    No competing interests declared.
  3. Daisuke Hishikawa

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  4. Ryo Morimoto

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    Ryo Morimoto, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  5. Fumie Hamano

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Fumie Hamano, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  6. Suzumi M Tokuoka

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Suzumi M Tokuoka, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  7. Miki Eto

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    Miki Eto, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  8. Miwa Tamura-Nakano

    Communal Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  9. Rieko Yanobu-Takanashi

    Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  10. Yoshiko Mukumoto

    Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology, Kobe, Japan
    Competing interests
    No competing interests declared.
  11. Hiroshi Kiyonari

    Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology, Kobe, Japan
    Competing interests
    No competing interests declared.
  12. Tadashi Okamura

    Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  13. Yoshihiro Kita

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Yoshihiro Kita, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  14. Hideo Shindou

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  15. Takao Shimizu

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    For correspondence
    tshimizu@ri.ncgm.go.jp
    Competing interests
    Takao Shimizu, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..

Ethics

Animal experimentation: All animal experiments were approved by and performed in accordance with the guidelines of the Animal Research Committee of National Center for Global Health and Medicine (12053, 13009, 14045), and the animal experimentation committee of the University of Tokyo (H09-144, P08-042).

Copyright

© 2015, Hashidate-Yoshida et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,118
    views
  • 1,358
    downloads
  • 186
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tomomi Hashidate-Yoshida
  2. Takeshi Harayama
  3. Daisuke Hishikawa
  4. Ryo Morimoto
  5. Fumie Hamano
  6. Suzumi M Tokuoka
  7. Miki Eto
  8. Miwa Tamura-Nakano
  9. Rieko Yanobu-Takanashi
  10. Yoshiko Mukumoto
  11. Hiroshi Kiyonari
  12. Tadashi Okamura
  13. Yoshihiro Kita
  14. Hideo Shindou
  15. Takao Shimizu
(2015)
Fatty acyl-chain remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport
eLife 4:e06328.
https://doi.org/10.7554/eLife.06328

Share this article

https://doi.org/10.7554/eLife.06328

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Santi Mestre-Fos, Lucas Ferguson ... Jamie HD Cate
    Research Article

    Stem cell differentiation involves a global increase in protein synthesis to meet the demands of specialized cell types. However, the molecular mechanisms underlying this translational burst and the involvement of initiation factors remains largely unknown. Here, we investigate the role of eukaryotic initiation factor 3 (eIF3) in early differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (NPCs). Using Quick-irCLIP and alternative polyadenylation (APA) Seq, we show eIF3 crosslinks predominantly with 3’ untranslated region (3’-UTR) termini of multiple mRNA isoforms, adjacent to the poly(A) tail. Furthermore, we find that eIF3 engagement at 3’-UTR ends is dependent on polyadenylation. High eIF3 crosslinking at 3’-UTR termini of mRNAs correlates with high translational activity, as determined by ribosome profiling, but not with translational efficiency. The results presented here show that eIF3 engages with 3’-UTR termini of highly translated mRNAs, likely reflecting a general rather than specific regulatory function of eIF3, and supporting a role of mRNA circularization in the mechanisms governing mRNA translation.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Ana Patrícia Graça, Vadim Nikitushkin ... Gerald Lackner
    Research Article

    Mycofactocin is a redox cofactor essential for the alcohol metabolism of mycobacteria. While the biosynthesis of mycofactocin is well established, the gene mftG, which encodes an oxidoreductase of the glucose-methanol-choline superfamily, remained functionally uncharacterized. Here, we show that MftG enzymes are almost exclusively found in genomes containing mycofactocin biosynthetic genes and are present in 75% of organisms harboring these genes. Gene deletion experiments in Mycolicibacterium smegmatis demonstrated a growth defect of the ∆mftG mutant on ethanol as a carbon source, accompanied by an arrest of cell division reminiscent of mild starvation. Investigation of carbon and cofactor metabolism implied a defect in mycofactocin reoxidation. Cell-free enzyme assays and respirometry using isolated cell membranes indicated that MftG acts as a mycofactocin dehydrogenase shuttling electrons toward the respiratory chain. Transcriptomics studies also indicated remodeling of redox metabolism to compensate for a shortage of redox equivalents. In conclusion, this work closes an important knowledge gap concerning the mycofactocin system and adds a new pathway to the intricate web of redox reactions governing the metabolism of mycobacteria.